Protagonist Therapeutics, Inc. (PTGX) - 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated February 27, 2024, reports the financial results for Protagonist Therapeutics, Inc. for the fourth quarter and full year ended December 31, 2023. The company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol PTGX.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K serves as a notification that results were reported and incorporates the detailed press release (Exhibit 99.1) by reference, but the specific financial figures are not contained within the body of this document.
Material Changes
The filing does not detail specific material changes versus prior periods. It references a corporate update and financial results contained in the attached press release, which is not included in the provided text.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, and contingencies are referenced as being part of the press release titled "Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update." The filing text itself does not contain these details.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for specific Q4 and full-year 2023 financial figures, as they are not listed in this 8-K.
- Verify the company's cash runway and burn rate from the detailed financial statements referenced in the press release.
- Check for any updates on clinical trial progress or corporate strategy mentioned in the "Corporate Update" section of the press release.
- Confirm the status of the company's emerging growth company election and any related accounting standard transitions.